Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

02. September 2025 08:00 ET | Quelle: Opus Genetics, Inc.

Opus Genetics Appoints Rob Gagnon as Chief Financial Officer

Opus Genetics Appoints Rob Gagnon as Chief Financial Officer
27. August 2025 08:00 ET | Quelle: Opus Genetics, Inc.

Opus Genetics Inherited Retinal Disease Programs Featured at Medical and Industry Conferences in September

Opus Genetics Inherited Retinal Disease Programs Featured at Medical and Industry Conferences in September
18. August 2025 08:00 ET | Quelle: Opus Genetics, Inc.

Opus Genetics Announces FDA Clearance of IND Application for Gene Therapy Candidate OPGx-BEST1

Opus Genetics Announces FDA Clearance of IND Application for Gene Therapy Candidate OPGx-BEST1
13. August 2025 16:30 ET | Quelle: Opus Genetics, Inc.

Opus Genetics Announces Financial Results for Second Quarter 2025 and Provides Corporate Update

Opus Genetics Announces Financial Results for Second Quarter 2025 and Provides Corporate Update
05. August 2025 08:00 ET | Quelle: Opus Genetics, Inc.

Opus Genetics to Participate in the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference

Opus Genetics to Participate in the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference
23. Juli 2025 08:00 ET | Quelle: Opus Genetics, Inc.

Opus Genetics and the Global RDH12 Alliance Partner to Advance RDH12 Gene Therapy for Inherited Childhood Blindness

Opus Genetics and the Global RDH12 Alliance Partner to Advance RDH12 Gene Therapy for Inherited Childhood Blindness
03. Juli 2025 16:30 ET | Quelle: Opus Genetics, Inc.

Opus Genetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Opus Genetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
26. Juni 2025 06:55 ET | Quelle: Opus Genetics, Inc.

Opus Genetics Announces VEGA-3 Phase 3 Trial Met its Primary Endpoint for Phentolamine Ophthalmic Solution 0.75% for the Treatment of Presbyopia

Opus Genetics Announces VEGA-3 Phase 3 Trial Met its Primary Endpoint for Phentolamine Ophthalmic Solution 0.75% for the Treatment of Presbyopia
23. Juni 2025 08:00 ET | Quelle: Opus Genetics, Inc.

Opus Genetics Awarded Non-Dilutive Funding from the RD Fund to Support Preclinical Development of OPGx-MERTK Program

Opus Genetics Awarded Non-Dilutive Funding from the RD Fund to Support Preclinical Development of OPGx-MERTK Program
02. Juni 2025 08:00 ET | Quelle: Opus Genetics, Inc.

Opus Genetics Announces LYNX-2 Phase 3 Trial Met its Primary Endpoint for Phentolamine Ophthalmic Solution 0.75% in Keratorefractive Patients with Visual Disturbances Under Mesopic, Low-Contrast Conditions

Opus Genetics Announces LYNX-2 Phase 3 Trial Met its Primary Endpoint for Phentolamine Ophthalmic Solution 0.75% in Keratorefractive Patients

Vorherige Seite

Nächste Seite